VivoSeq
Hematology

Myelofibrosis

128

Pipeline Programs↗

54

Active Trials↗

47

Companies Involved↗

Myelofibrosis is a highly competitive landscape with 128 programs across 47 companies. The most active players are Taiga Biotechnologies, Inc., Samus Therapeutics, Inc., Eli Lilly. 5 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

76/100

Pipeline Velocity

37/100

Mech. Concentration

4/100

Completion Rate

66/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Taiga Biotechnologies, Inc.

1 program

Phase 1S

Samus Therapeutics, Inc.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1P

Prism Pharmaceuticals

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

116 of 131 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody75%Protein / enzyme65%RNA therapy1<1%Cell therapy1<1%

Small molecule leads; the ring shows all 131 classified programs, each share of the total. Modality classified for 99% of 140 pipeline programs.

Analysis

Trial Status

165

clinical trials

Completed65 · 39%
Terminated28 · 17%
Recruiting25 · 15%
Active, not recruiting20 · 12%
Unknown status11 · 7%
Not yet recruiting9 · 5%
Other7 · 4%

Clinical Trials

Trial Activity

165 trials

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT05835466·26 enrolled
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04370301·20 enrolled
Study of Canakinumab in Patients With Myelofibrosis
Recruiting·—·Phase 2·NCT05467800·14 enrolled
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06345495·30 enrolled
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT06073847·137 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
Recruiting·GGeron Corporation·Phase 1·NCT05371964·36 enrolled
A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis
Recruiting·SSuzhou Junjing BioSciences Co., Ltd.·Phase 1/2·NCT06909136·49 enrolled
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05714072·18 enrolled
Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis
Recruiting·UUniversity of Utah·Phase 1·NCT05535764·18 enrolled
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
Recruiting·CChengdu Zenitar Biomedical Technology Co., Ltd·Phase 2·NCT06457425·75 enrolled
Clonal Architecture of ASXL1-mutated Myelofibrosis
Recruiting·UUniversity Hospital, Angers·N/A·NCT05710211·50 enrolled
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Recruiting·GSK logoGSK·Phase 2·NCT06517875·56 enrolled
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Recruiting·CChengdu Zenitar Biomedical Technology Co., Ltd·Phase 3·NCT07317700·105 enrolled
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Recruiting·TThe University of Hong Kong·Phase 2·NCT06770842·20 enrolled
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Recruiting·Takeda logoTakeda·Phase 2·NCT05037760·135 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)